Clinical Trials
6
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
Phase 1
Active, not recruiting
- Conditions
- Breast CancerHead and Neck Squamous Cell CarcinomaMelanomaNon Small Cell Lung CancerPancreatic CancerLiver CancerColorectal Cancer
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03552718
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02751528
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Sanford Cancer Center, Sioux Falls, South Dakota, United States
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- NantBioScience, Inc.
- Registration Number
- NCT02582827
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Phase 2
Terminated
- Conditions
- UnresectableAdenocarcinoma of the PancreasLocally Advanced
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01318642
- Locations
- 🇬🇧
Guys Hospital, London, United Kingdom
🇬🇧Research Site, Preston, United Kingdom
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00891930
- Prev
- 1
- 2
- Next
News
No news found